Published guidance, NICE advice and quality standards | Guidance

Showing 251 to 260 of 872

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Eptinezumab for preventing migraine	TA871	1 March 2023	1 March 2023
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	TA872	28 February 2023	28 February 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	TA870	22 February 2023	22 February 2023
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)	TA867	16 February 2023	16 February 2023
Vutrisiran for treating hereditary transthyretin-related amyloidosis	TA868	15 February 2023	15 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	TA865	8 February 2023	8 February 2023
Regorafenib for previously treated metastatic colorectal cancer	TA866	8 February 2023	8 February 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis	TA861	1 February 2023	1 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	TA862	1 February 2023	1 February 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over	TA863	1 February 2023	1 February 2023